ABOS
Income statement / Annual
Last year (2023), Acumen Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Acumen Pharmaceuticals, Inc.'s net income was -$52.37 M.
See Acumen Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$1.44 M
|
$1.70 M
|
| Cost of Revenue |
$42.32 M |
$169,000.00 |
$4,000.00 |
$7,997.00 |
$8,576.00 |
| Gross Profit |
-$42.32 M |
-$169,000.00 |
-$4,000.00 |
$1.43 M |
$1.69 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0.99 |
0.99 |
| Research and Development
Expenses |
$42.32 M
|
$32.36 M
|
$12.31 M
|
$8.00 M
|
$8.58 M
|
| General & Administrative
Expenses |
$18.82 M
|
$12.88 M
|
$7.28 M
|
$1.35 M
|
$926,000.00
|
| Selling & Marketing
Expenses |
-$184,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$18.82 M
|
$12.88 M
|
$7.28 M
|
$1.35 M
|
$926,000.00
|
| Other Expenses |
$0.00 |
-$11,000.00 |
$51,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$20.26 M |
$45.24 M |
$19.58 M |
$9.35 M |
$9.50 M |
| Cost And Expenses |
$62.58 M |
$45.24 M |
$19.58 M |
$9.35 M |
$9.50 M |
| Interest Income |
$10.79 M |
$2.39 M |
$84,000.00 |
$1,000.00 |
$45,000.00 |
| Interest Expense |
-$581,000.00 |
-$2.38 M |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$61,000.00
|
$169,000.00
|
$4,000.00
|
$7.91 M
|
$7.81 M
|
| EBITDA |
-$61.08 M
|
-$45.07 M
|
$61.58 M
|
-$8.50 M
|
-$7.66 M
|
| EBITDA Ratio |
0 |
0 |
0 |
-5.92 |
-4.51 |
| Operating Income Ratio
|
0
|
0
|
0
|
-5.51
|
-4.6
|
| Total Other
Income/Expenses Net |
$8.77 M
|
$2.38 M
|
-$162.18 M
|
$587,000.00
|
-$102,000.00
|
| Income Before Tax |
-$52.37 M |
-$42.86 M |
-$100.61 M |
-$7.33 M |
-$7.91 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
-5.1
|
-4.66
|
| Income Tax Expense |
$0.00 |
-$2.38 M |
$81.07 M |
-$1,000.00 |
-$45,000.00 |
| Net Income |
-$52.37 M |
-$40.48 M |
-$181.68 M |
-$7.32 M |
-$7.86 M |
| Net Income Ratio |
0 |
0 |
0 |
-5.1 |
-4.63 |
| EPS |
-1.08 |
-1 |
-4.49 |
-0.18 |
-0.2 |
| EPS Diluted |
-1.08 |
-1 |
-4.49 |
-0.18 |
-0.2 |
| Weighted Average Shares
Out |
$48.49 M
|
$40.60 M
|
$40.47 M
|
$40.15 M
|
$40.15 M
|
| Weighted Average Shares
Out Diluted |
$48.61 M
|
$40.60 M
|
$40.47 M
|
$40.15 M
|
$40.15 M
|
| Link |
|
|
|
|
|
